Eli Lilly’s (LLY) product portfolio includes drugs in its Animal Health segment, including companion animal and food products. This segment is also known as Elanco and reported revenues of $740.6 million during 3Q17, representing a 5% YoY (year-over-year) rise, compared with revenues of $706.2 million in 3Q16.
Elanco revenues include the sales of companion animal products and food animal products, both in the US and outside the US. LLY’s US animal health sales rose 4% YoY to $353.1 million during 3Q17, while non-US sales rose 5% to $387.6 million.
US revenue growth was driven by a 63% YoY rise in revenues from US companion animal products, due to the inclusion of Boehringer Ingelheim Vetmedica’s US business of canine, feline, and rabies vaccines. This growth was partially offset by a 22% fall in revenues from US food and other products.
Non-US revenue growth was driven by a 7% YoY rise in revenues from food and other products, offset by a 1% fall in revenues from companion animal products.
Companion animal products
LLY’s companion animal products reported revenues of $252.2 million during 3Q17, representing a 35% YoY rise in revenues. This growth was driven by the inclusion of Vetmedica’s US canine, feline, and rabies vaccines, which contributed $61.2 million to 3Q17 revenues. Wholesaler buying patterns in US markets also had a positive impact on the total revenues of companion animal products in 3Q17.
US sales of companion animal products total $170.3 million in 3Q17, representing a 63% YoY rise, while non-US sales totaled $81.9 million, representing a 3% YoY fall at constant exchange rates. These results were partially offset by a 2% benefit from foreign exchange.
Food and other products
Animal food and other products reported revenues of $488.4 million during 3Q17, representing a 6% YoY fall. US sales for food and other products fell 22% YoY to $182.8 million during 3Q17, while non-US sales rose 6% at constant exchange rates to $305.7 million. Foreign exchange rates had a 1% positive impact during 3Q17.